Skip to main content
SpringerLink
Log in

Perceived Risks from Live Viral Vaccines

  • Chapter
  • First Online:
Vaccinophobia and Vaccine Controversies of the 21st Century

  • 3696 Accesses

Abstract

Live viral vaccines work by exposing the immune system to an attenuated form of viruses that typically cause infections. The immune response engendered by these vaccines provides protection with subsequent exposure to wild type viruses, resulting in either no disease or a milder form of disease with fewer associated complications. This chapter discusses both real and perceived adverse effects associated with the more commonly used live virus vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007;150:306–10.

    Article  PubMed  Google Scholar 

  2. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512–7.

    Article  PubMed  Google Scholar 

  3. Mauricich SM, Neul JL, Lotze TE, et al. Neurologic complications associated with influenza A in children during the 2003–2004 influenza season in Houston, Texas. Pediatrics. 2004;114:e626.

    Article  Google Scholar 

  4. Thompson MG, Shay DK, Zhou H, et al. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR. 2010;59:1057–62.

    Google Scholar 

  5. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361:1935–44.

    Article  PubMed  CAS  Google Scholar 

  6. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. 2010;59:RR8.

    Google Scholar 

  7. Centers for Disease Control and Prevention. Expansion of use of live attenuated influenza vaccine (FluMist®) to children aged 2–4 years and other FluMist changes for the 2007–2008 influenza season. MMWR. 2007;56:1217–9.

    Google Scholar 

  8. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338:1405–12.

    Article  PubMed  CAS  Google Scholar 

  9. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685–96.

    Article  PubMed  CAS  Google Scholar 

  10. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168–75.

    Article  PubMed  CAS  Google Scholar 

  11. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994;69:68–76.

    Article  Google Scholar 

  12. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361:1260–7.

    Article  PubMed  CAS  Google Scholar 

  13. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860–9.

    Article  PubMed  Google Scholar 

  14. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138–44.

    Article  PubMed  Google Scholar 

  15. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25:870–9.

    Article  PubMed  Google Scholar 

  16. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25:590–5.

    Article  PubMed  Google Scholar 

  17. World Health Organization (WHO) fact sheet N286, October 2011 at www.who.int/mediacentre/factsheets/fs286/en/

  18. Griffin DE, Pan CH. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol. 2009;330:1.

    PubMed  Google Scholar 

  19. Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis. 2005;192:1686–93.

    Article  PubMed  Google Scholar 

  20. Roush SW, Murphy TV. Vaccine-preventable disease table working group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;208:2155–63.

    Article  Google Scholar 

  21. Centers for Disease Control and Prevention. Measles, mumps, and rubella- vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1998;47:RR8.

    Google Scholar 

  22. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J. 1999;18:42–8.

    Article  PubMed  CAS  Google Scholar 

  23. Wood DL, Brunell PA. Measles control in the United States: problems of the past and challenges for the future. Clin Microbiol Rev. 1995;8:260–7.

    PubMed  CAS  Google Scholar 

  24. Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia, PA: Saunders Elsevier; 2004. p. 389–40.

    Google Scholar 

  25. Mathias RG, Meekison WG, Arcand TA, Schechter MT. The role of secondary vaccine failures in measles outbreaks. Am J Public Health. 1989;79:475–8.

    Article  PubMed  CAS  Google Scholar 

  26. Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16–17 March 2000. J Infect Dis. 2004;189 Suppl 1:S43–7.

    Article  PubMed  Google Scholar 

  27. CDC. Measles- United States, January–May 20, 2011. MMWR 2011; 60: 666–8.

    Google Scholar 

  28. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637–41.

    Article  PubMed  CAS  Google Scholar 

  29. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn’s disease. J Med Virol. 1993;39:345–53.

    Article  PubMed  CAS  Google Scholar 

  30. Daszak P, Purcell M, Lewin J, et al. Detection and comparative analysis of persistent measles virus infection in Crohn’s disease by immunogold electron microscopy. J Clin Pathol. 1997;50:299–304.

    Article  PubMed  CAS  Google Scholar 

  31. Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella vaccines. Bull World Health Organ. 2000;78:199–204.

    PubMed  CAS  Google Scholar 

  32. Haga Y, Funakoshi O, Kuroe K, et al. Absence of measles viral genomic sequence in intestinal tissues from Crohn’s disease by nested polymerase chain reaction. Gut. 1996;38:211–5.

    Article  PubMed  CAS  Google Scholar 

  33. Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children (Review). Cochrane Database Syst Rev. 2005;19, CD004407.

    Google Scholar 

  34. IOM (Institute of Medicine). Adverse effects of vaccines: evidence and causality. Washington DC: The National Academies Press; 2011.

    Google Scholar 

  35. Halsey NA, Hyman SL, the Conference Writing Panel. Measles-Mumps-Rubella vaccine and autistic spectrum disorder: Report from the new challenges in childhood immunizations conference convened in Oak Brook, Illinois, June 12–13, 2000

    Google Scholar 

  36. Editors of the Lancet. Retraction—Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 2010;375:445.

    Article  Google Scholar 

  37. Brown KF, Long SJ, Ramsay M, et al. UK parents’ decision-making about measles-mumps-rubella (MMR) vaccine 10 years after the MMR-autism controversy: a qualitative analysis. Vaccine. 2012;30(10):1855–64.

    Article  PubMed  Google Scholar 

  38. Smith PJ, Humiston SG, Marcuse EK, et al. Parental delay or refusal of vaccine doses, childhood vaccination coverage at 24 months of age, and the health belief model. Public Health Rep. 2011;126:135–46.

    PubMed  Google Scholar 

  39. Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev. 2010;236:176–89.

    Article  PubMed  CAS  Google Scholar 

  40. Avota E, Gassert E, Schneider-Schaulies S. Measles virus-induced immunosuppression: from effectors to mechanisms. Med Microbiol Immunol. 2010;199:227–37.

    Article  PubMed  CAS  Google Scholar 

  41. Starr S, Berkovich S. Effects of measles, gamma-globulin-modified measles and vaccine measles on the tuberculin test. New Engl J Med. 1964;270:386–91.

    Article  PubMed  CAS  Google Scholar 

  42. Hussey GD, Goddard EA, Hughes J, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune responses in infants. J Infect Dis. 1996;173:1320–6.

    Article  PubMed  CAS  Google Scholar 

  43. Centers for Disease Control and Prevention. General recommendations on immunizations: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60(2):3–58.

    Google Scholar 

  44. Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics. 2003;112:e98.

    Article  PubMed  Google Scholar 

  45. Ternavasio-de la Vega HG, Boronat M, Ojeda A, et al. Mumps orchitis in the post-vaccine era (1967–2009). Medicine. 2010;89:96–116.

    Article  PubMed  Google Scholar 

  46. Yung CF, Andrews N, Bukasa A, et al. Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis. 2011;17:661–7.

    Article  PubMed  Google Scholar 

  47. Centers for Disease Control and Prevention. Mumps epidemic—United Kingdom, 2004–2005. MMWR. 2006;55:173–5.

    Google Scholar 

  48. Centers for Disease Control and Prevention. Update: Multistate outbreak of mumps—United States, January 1- May 2, 2006. MMWR. 2006;55:559–63.

    Google Scholar 

  49. Schluter WW, Reef SE, Redd SC, Dykewicz CA. Changing epidemiology of congenital rubella syndrome in the United States. J Infect Dis. 1998;178:636.

    Article  PubMed  CAS  Google Scholar 

  50. Plotkin SA, Reef S. Rubella vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004. p. 707–43.

    Google Scholar 

  51. Centers for Disease Control and Prevention. Elimination of rubella and congenital rubella syndrome—United States, 1969–2004. MMWR. 2005;54:279–82.

    Google Scholar 

  52. Reef SE, Redd SB, Abernathy E, et al. Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States. J Infect Dis. 2011;204:S593–7.

    Article  PubMed  Google Scholar 

  53. Centers for Disease Control and Prevention. Progress toward control of rubella and prevention of congenital rubella syndrome—worldwide, 2009. MMWR. 2010;59:1307–10.

    Google Scholar 

  54. Centers for Disease Control and Prevention. Imported case of congenital rubella syndrome—New Hampshire, 2005. MMWR. 2005;54:1160–3.

    Google Scholar 

  55. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New Engl J Med. 2001;345:656–61.

    Article  PubMed  CAS  Google Scholar 

  56. Vestergaard M, Hviid A, Meldgaard Madsen K, et al. MMR vaccination and febrile seizures: Evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292:351–7.

    Article  PubMed  CAS  Google Scholar 

  57. Beeler J. Thrombocytopenia after immunization with measles vaccines: Review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J. 1996;15:88–90.

    Article  PubMed  CAS  Google Scholar 

  58. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876–86.

    Article  PubMed  CAS  Google Scholar 

  59. Rajantie J, Zeller B, Treutiger I, Rosthöj S. Vaccination associated thrombocytopenic purpura in children. Vaccine. 2007;25:1838–40.

    Article  PubMed  CAS  Google Scholar 

  60. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55:107–11.

    Article  PubMed  Google Scholar 

  61. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccine effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106:e62.

    Article  PubMed  CAS  Google Scholar 

  62. Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink Project. Pediatrics. 1997;100:767–71.

    Article  PubMed  CAS  Google Scholar 

  63. Castillo-Solórzano C, Reef SE, Morice A, et al. Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, The Americas 2001–2008. J Infect Dis. 2011;204:S713–7.

    Article  PubMed  Google Scholar 

  64. Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr. 1993;122:204–11.

    Article  PubMed  CAS  Google Scholar 

  65. Maldonado Y. Polioviruses. In: Long SS, Pickering LK, Prober CG, editors. Principles and practices of pediatric infectious diseases. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2008. p. 1146–9.

    Chapter  Google Scholar 

  66. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol. 2003;13:277–91.

    Article  PubMed  Google Scholar 

  67. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication—the Americas, 1994. MMWR. 1994;43:720–2.

    Google Scholar 

  68. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission—worldwide, January 2010- March 2011. MMWR. 2011;60:582–6.

    Google Scholar 

  69. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49:RR5.

    Google Scholar 

  70. Parashar UD, Hummelman EG, Bresee JS, et al. Global Illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565–72.

    Article  PubMed  Google Scholar 

  71. Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. J Infect Dis. 2007;195:1117–25.

    Article  PubMed  Google Scholar 

  72. Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:RR2.

    Google Scholar 

  73. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine—United States, 1998-1999. MMWR. 1999;48:577–81.

    Google Scholar 

  74. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344:564–72.

    Article  PubMed  CAS  Google Scholar 

  75. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33.

    Article  PubMed  CAS  Google Scholar 

  76. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22.

    Article  PubMed  CAS  Google Scholar 

  77. Salinas B, Pérez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. Pediatr Infect Dis J. 2005;24:807–16.

    Article  PubMed  Google Scholar 

  78. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J. 2011;30:S56–60.

    Article  PubMed  Google Scholar 

  79. Centers for Disease Control and Prevention. Reduction in rotavirus after vaccine introduction—United States, 2000–2009. MMWR. 2009;58:1146–9.

    Google Scholar 

  80. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: Analysis of hospital discharge data from 18 US states. J Infect Dis. 2010;201:1617–24.

    Article  PubMed  Google Scholar 

  81. Centers for Disease Control and Prevention. Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR. 2001;50:RR-10.

    Google Scholar 

  82. Eyler J. Smallpox in history: The birth, death, and impact of a dread disease. J Lab Clin Med. 2003;142:216–20.

    Article  PubMed  Google Scholar 

  83. Parrino J, Graham BS. Smallpox vaccines: Past, present, and future. J Allergy Clin Immunol. 2006;118:1320–6.

    Article  PubMed  CAS  Google Scholar 

  84. Centers for Disease Control and Prevention. Smallpox vaccinations and adverse reactions. MMWR. 2003;52:RR-4.

    Google Scholar 

  85. Grabenstein JD, Winkenwerder Jr W. US military smallpox vaccination program experience. JAMA. 2003;289:3278–82.

    Article  PubMed  Google Scholar 

  86. Centers for Disease Control and Prevention. Update: Cardiac and other adverse events following civilian smallpox vaccination—United States, 2003. MMWR. 2003;52:639–42.

    Google Scholar 

  87. Centers for Disease Control and Prevention. Cardiac deaths after a mass smallpox vaccination campaign—New York City, 1947. 2003;52:933–6.

    Google Scholar 

  88. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: Trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182:383–90.

    Article  PubMed  CAS  Google Scholar 

  89. Ziebold C, von Kries R, Lang R, Weigl J, Schmitt HJ. Severe complications of varicella in previously healthy children in Germany: A 1-year survey. Pediatrics. 2001;108:e79.

    Article  PubMed  CAS  Google Scholar 

  90. Minodier P, Bidet P, Rallu F, et al. Clinical and microbiologic characteristics of group A streptococcal necrotizing fasciitis in children. Pediatr Infect Dis J. 2009;28:541–3.

    Article  PubMed  Google Scholar 

  91. Centers for Disease Control and Prevention. Varicella In: Epidemiology and Prevention of Vaccine Preventable Diseases. The Pink Book: Course textbook, 12th edition, April 2011.

    Google Scholar 

  92. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132–7.

    Article  PubMed  Google Scholar 

  93. Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56:RR4.

    Google Scholar 

  94. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: A review of successes and challenges. Pediatrics. 2008;122:e744.

    Article  PubMed  Google Scholar 

  95. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. New Engl J Med. 2005;352:450–8.

    Article  PubMed  CAS  Google Scholar 

  96. Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis. 2008;197:S82–9.

    Article  PubMed  Google Scholar 

  97. Chaves SS, Lopez AS, Watson TL, et al. Varicella in infants: after implementation of the US varicella vaccination program. Pediatrics. 2011;128:1071–7.

    Article  PubMed  Google Scholar 

  98. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella vaccine: Efficacy trial in healthy children. N Engl J Med. 1984;310:1409–15.

    Article  PubMed  CAS  Google Scholar 

  99. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: A 10-year review. J Infect Dis. 2008;197:S165–9.

    Article  PubMed  Google Scholar 

  100. Gershon AA, LaRussa P, Hardy I, et al. Varicella vaccine: the American experience. J Infect Dis. 1992;166(Suppl I):S63–8.

    Article  PubMed  Google Scholar 

  101. Hardy I, Gershon AA, Steinberg SP, et al. The incidence of zoster after immunization with live attenuated varicella vaccine: A study in children with leukemia. N Engl J Med. 1991;325:1545–50.

    Article  PubMed  CAS  Google Scholar 

  102. Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR. 2011;60:1528.

    Google Scholar 

  103. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.

    Article  PubMed  CAS  Google Scholar 

  104. Tyring SK, Diaz-Mitoma F, Padget LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine. 2007;25:1877–83.

    Article  PubMed  CAS  Google Scholar 

  105. Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30:904–10.

    Article  PubMed  CAS  Google Scholar 

  106. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305:160–6.

    Article  PubMed  CAS  Google Scholar 

  107. Centers for Disease Control and Prevention. Licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR 2005; 1212–4.

    Google Scholar 

  108. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27:4656–61.

    Article  PubMed  Google Scholar 

  109. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126:e1.

    Article  PubMed  Google Scholar 

  110. Reisinger KS, Hoffman Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad®) given to 4-to 6-year old healthy children vaccinated previously with M-M-RII® and Varivax®. Pediatrics. 2006;117:265–72.

    Article  PubMed  Google Scholar 

  111. Centers for Disease Control and Prevention. Use of combination measles, mumps, rubella and varicella vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2010;59:RR3.

    Google Scholar 

  112. Centers for Disease Control and Prevention. Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR. 2002;51:RR17.

    Google Scholar 

  113. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850–6.

    Article  PubMed  Google Scholar 

  114. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax® and YF-VAX®) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66:533–41.

    PubMed  CAS  Google Scholar 

  115. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98–104.

    Article  PubMed  CAS  Google Scholar 

  116. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine. 2011;29:4544–55.

    Article  PubMed  CAS  Google Scholar 

  117. Centers for Disease Control and Prevention. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR. 1996;45:603–6.

    Google Scholar 

  118. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1992;11:1008–14.

    Article  PubMed  CAS  Google Scholar 

  119. Taweesith W, Puthanakit T, Kowitdamrong E, et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2011;30:320–4.

    Article  PubMed  Google Scholar 

  120. Armenian SH, Han JY, Dunaway TM, Church JA. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2006;25:368–70.

    Article  PubMed  Google Scholar 

  121. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305–10.

    Article  PubMed  CAS  Google Scholar 

  122. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995;332:1262–6.

    Article  PubMed  CAS  Google Scholar 

  123. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998;133:624–8.

    Article  PubMed  CAS  Google Scholar 

  124. Kelso JM. Administration of influenza vaccines to patients with egg allergy. J Allergy Clin Immunol. 2010;125:800–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Infectious Diseases, University of California San Diego, Rady Children’s Hospital San Diego, San Diego, CA, USA

    Alice Pong M.D. & Mark Sawyer M.D.

Authors
  1. Alice Pong M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Sawyer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alice Pong M.D. .

Editor information

Editors and Affiliations

  1. , School of Medicine, Creighton University, North 30th Street,Suite 6814 601, Omaha, 68131, Nebraska, USA

    Archana Chatterjee

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pong, A., Sawyer, M. (2013). Perceived Risks from Live Viral Vaccines. In: Chatterjee, A. (eds) Vaccinophobia and Vaccine Controversies of the 21st Century. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7438-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7438-8_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7437-1

  • Online ISBN: 978-1-4614-7438-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation